OMKAR PHARMACHEM LTD.

Omkar Pharmachem Ltd has fixed September 23, 2026, as the cut-off date for shareholders to be eligible for e-voting at the 31st Annual General Meeting (AGM). This is in compliance with Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014. The company has partnered with Central Depository Services Limited (CDSL) to facilitate e-voting for shareholders holding shares in both physical and demat modes.

Omkar Pharmachem Ltd has announced its 31st Annual General Meeting (AGM) for the financial year 2025-26. The company has filed the 31st Annual Report along with the Notice of AGM. Key agenda items include the adoption of audited financial statements for FY25-26, the re-appointment of a director retiring by rotation, and the approval of material related party transactions up to ₹25,00,000 for FY26-27 with Key Managerial Personnel (KMPs). The AGM is scheduled for September 30, 2026, in Ahmedabad.

Omkar Pharmachem Ltd has announced its 31st Annual General Meeting (AGM) to be held on Wednesday, September 30, 2026, at 10:30 a.m. at Hotel Kanak, Ahmedabad. The meeting will cover ordinary business, including the adoption of audited financial statements for the year ended March 31, 2026, and the re-appointment of a director retiring by rotation. Special business includes considering and approving material related party transactions up to ₹25,00,000 for the financial year 2026-27, provided they are at arm's length and in the ordinary course of business. Members will have the facility to cast their vote electronically on all resolutions.

Omkar Pharmachem Ltd announced the outcome of its Board Meeting held on August 31, 2026. The board approved the notice for the 31st Annual General Meeting (AGM) scheduled for September 30, 2026. Additionally, the Director's report for the financial year ended March 31, 2026, was approved. M/s Maulik Bhavsar & Associates were appointed as scrutinizers for the AGM voting process. The meeting also addressed material related party transactions.

Omkar Pharmachem Ltd has announced its unaudited financial results for the quarter ended June 30, 2026. The results were approved by the Board of Directors on August 13, 2026. The company has complied with SEBI (LODR) Regulations, 2015, by submitting these results along with a limited review report. The financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34).

Omkar Pharmachem Ltd announced that its Board of Directors met on August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company also received the Limited Review Report from its auditors, Dipal R. Shah & Co., for the same period. The financial results indicate a net loss for the quarter. The meeting commenced at 3:30 PM and concluded at 4:10 PM.

Omkar Pharmachem Ltd has announced that its Board of Directors will convene on August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the limited review report. The company also confirmed that the trading window for its securities will remain closed until August 15, 2026, for designated persons and their immediate relatives, in line with SEBI regulations and the company's code of conduct.

Omkar Pharmachem Limited has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading Regulations), 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the company's Unaudited Financial Results for the quarter ended June 30, 2026. The date for the board meeting to approve these results will be announced separately.

Omkar Pharmachem Ltd's board meeting on May 30, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The meeting commenced at 05:00 P.M. and concluded at 05:40 P.M. The results have been audited by Dipal R. Shah & Co., who have issued an independent auditor's report stating that the financial results give a true and fair view in conformity with applicable accounting standards.

Omkar Pharmachem Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The results, along with the auditor's report, statement of assets and liabilities, cash flow statement, and declaration under Regulation 33(3)(d) of SEBI Regulations 2015, were approved by the Board of Directors in their meeting held on May 30, 2026. The audit was conducted by DIPALR. SHAH & CO., who issued an independent auditor's report stating that the financial results give a true and fair view in conformity with Indian Accounting Standards.